SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3...

Leukemia 2012 / 8 Vol. 26; Iss. 8

SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants

Cao, Z-X, Liu, J-J, Zheng, R-L, Yang, J, Zhong, L, Xu, Y, Wang, L-J, Zhang, C-H, Wang, B-L, Ma, S, Wang, Z-R, Xie, H-Z, Wei, Y-Q, Yang, S-Y
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
26
Language:
english
Journal:
Leukemia
DOI:
10.1038/leu.2012.67
Date:
August, 2012
File:
PDF, 381 KB
english, 2012
Conversion to is in progress
Conversion to is failed